Page last updated: 2024-11-07

ud cg 212 cl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

UD CG 212 Cl: pimobendan metabolite; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122344
SCHEMBL ID11290551
SCHEMBL ID7322526
MeSH IDM0138178

Synonyms (11)

Synonym
udcg-212
ud cg 212 cl
ud-cg-212-cl
udcg 212
3(2h)-pyridazinone, 4,5-dihydro-6-(2-(4-hydroxyphenyl)-1h-benzimidazol-5-yl)-5-methyl-, monohydrochloride
SCHEMBL11290551
77469-70-6
SCHEMBL7322526
3-[2-(4-hydroxyphenyl)-3h-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one;hydrochloride
4-[5-(6-hydroxy-4-methyl-4,5-dihydropyridazin-3-yl)-1,3-dihydro-2h-benzimidazol-2-ylidene]cyclohexa-2,5-dien-1-one--hydrogen chloride (1/1)
DTXSID70998667
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (29.63)18.7374
1990's16 (59.26)18.2507
2000's3 (11.11)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.96 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.14%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (89.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]